• PPM-18: Precision iNOS Expression Inhibition in Inflammation

  2026-05-29

  PPM-18 (N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide) is a potent, selective inhibitor of inducible nitric oxide synthase (iNOS) expression via NF-κB pathway blockade. It demonstrates robust anti-inflammatory effects in vitro and in vivo, with well-defined solubility and application parameters. PPM-18 provides a validated solution for modulating inflammatory and immune responses in preclinical models.

• DiscoveryProbe FDA-approved Drug Library: Applied Screening

  2026-05-29

  The DiscoveryProbe FDA-approved Drug Library empowers researchers with a clinically rich, highly reproducible compound set for high-throughput drug repositioning and mechanistic disease modeling. Discover how optimized protocols, troubleshooting insights, and real-world case studies translate this compound library into accelerated breakthroughs for cancer and neurodegenerative disease research.

• Localized Muscle BDNF Release Directs Early Synaptic Formati

  2026-05-28

  This study reveals that spatially localized, activity-dependent release of muscle-derived BDNF is crucial for the initial assembly of postsynaptic acetylcholine receptor clusters at neuromuscular junctions. The findings illuminate the roles of BDNF trafficking, proteolytic processing, and matrix metalloproteinase activity in orchestrating early synaptic differentiation, providing a mechanistic framework for future in vitro and in vivo research.

• Modeling ampC/ampD-Mediated Resistance in P. aeruginosa

  2026-05-28

  This study advances understanding of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam by dissecting the individual and combined effects of ampC and ampD mutations using semi-mechanistic PK/PD modeling. The findings provide nuanced, time-resolved insights into acquired and adaptive resistance, with practical implications for antimicrobial development and resistance surveillance.

• HOBt (1-Hydroxybenzotriazole) in Modern Amide Bond Formation

  2026-05-27

  HOBt (1-Hydroxybenzotriazole) is a pivotal reagent for minimizing epimerization and maximizing yield during peptide and amide bond synthesis. This article translates mechanistic insights and recent literature—especially in drug discovery—into actionable protocols and troubleshooting strategies for researchers seeking high-fidelity results.

• Antiarrhythmic Agents and KCa2 Channel Modulation in AF Rese

  2026-05-27

  This article analyzes how current antiarrhythmic drugs, including Dronedarone (Multaq), interact with small conductance calcium-activated potassium (KCa2) channels—an emerging atrial-selective target in atrial fibrillation (AF) research. The reviewed study systematically evaluates whether these agents directly inhibit KCa2 channels at clinically relevant concentrations, shedding light on their mechanistic limitations and future directions for atrial arrhythmia pharmacology.

• Decoding mRNA Delivery: Advanced Assay Design with EZ Cap™ C

  2026-05-26

  Discover how EZ Cap™ Cy5 EGFP mRNA (5-moUTP) empowers precise mRNA delivery and translation efficiency assays with dual-fluorescence tracking and immune-evasive chemistry. This in-depth article uniquely explores optimization strategies and translational insights for next-generation gene delivery research.

• Capture-and-Release Strategy Enhances LFA Sensitivity via Am

  2026-05-26

  The referenced study introduces a 'capture-and-release' (AmpliFold) methodology to improve lateral flow assay (LFA) sensitivity by enabling high-affinity rebinding and signal amplification. This approach leverages cleavable linkers and dual-affinity nanoparticles to overcome kinetic limitations, achieving up to 16-fold lower detection limits in HER2 antigen assays, with meaningful implications for decentralized diagnostic workflows.

• IEM 1460: Decoding Selective AMPA Receptor Blockade in Neuro

  2026-05-25

  Explore the unique role of IEM 1460 as a selective AMPA receptor blocker for advanced excitotoxicity and neuroprotection research. This article delivers a mechanistic deep dive and protocol insights, distinguishing itself from prior content by focusing on translational assay design and evidence-based decision-making.

• Veratridine: Voltage-Gated Sodium Channel Opener in Precisio

  2026-05-25

  Veratridine stands as the benchmark voltage-gated sodium channel opener, enabling precise modeling of excitability in neuroscience, cardiomyocyte differentiation, and advanced screening assays. This guide translates the latest bench workflows and reference breakthroughs into actionable protocols, troubleshooting insights, and domain-bridging best practices.

• Pifithrin-α (PFTα): A Benchmark p53 Inhibitor for Apoptosis

  2026-05-24

  Pifithrin-α (PFTα) is a validated p53 inhibitor that blocks p53-dependent apoptosis and cell cycle arrest. It is widely used in models of DNA damage, ferroptosis, and neuroprotection. Recent evidence confirms its protective effects against p53-mediated neuronal loss after toxic exposure.

• Risedronate Sodium: FPPS Inhibitor Workflows in Bone and Lun

  2026-05-23

  Risedronate Sodium is redefining experimental approaches in bone metabolism and pulmonary research as a potent FPPS inhibitor. This guide delivers actionable protocols, troubleshooting strategies, and translational insights, spotlighting its unique repurposing potential and nano-delivery innovations.

• Microbiome and Metabolome Shifts in E. tenella-Infected Chic

  2026-05-22

  This study uses high-resolution microbiome and metabolomics profiling to reveal how ethanamizuril, sulfachlorpyridazine, and their combination modulate cecal microbial communities and metabolic signatures in chickens challenged with Eimeria tenella. The findings establish microbiota and metabolite changes as informative markers for drug response, with implications for designing more effective interventions against avian coccidiosis.

• Cinoxacin in Gram-Negative Research: Protocols & Pitfalls

  2026-05-22

  Cinoxacin, a quinolone antibiotic from APExBIO, empowers researchers to dissect bacterial DNA synthesis inhibition with precision in Gram-negative infection and antibiotic resistance studies. This guide details advanced workflows, troubleshooting, and key innovations that drive reproducibility and impact in urinary tract infection and bacterial prostatitis research.

• AZD2461: Novel PARP Inhibitor for DNA Repair in Breast Cance

  2026-05-21

  AZD2461 is a novel PARP inhibitor with nanomolar potency, designed to modulate DNA repair and overcome Pgp-mediated drug resistance in breast cancer research. Its efficacy is demonstrated by robust cytotoxicity in BRCA1-mutated models and improved relapse-free survival in vivo. This dossier presents atomic, verifiable evidence for AZD2461's application and boundaries.

15370 records 6/1025 page Previous Next First page 上5页 678910 下5页 Last page